CNS Pharmaceuticals (NASDAQ:CNSP – Get Free Report) issued its earnings results on Monday. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.03, FiscalAI reports.
CNS Pharmaceuticals Stock Up 3.5%
NASDAQ:CNSP opened at $2.99 on Monday. CNS Pharmaceuticals has a twelve month low of $1.90 and a twelve month high of $10.54. The stock’s 50-day simple moving average is $4.96 and its 200 day simple moving average is $4.47. The firm has a market capitalization of $4.37 million, a PE ratio of -0.13 and a beta of 3.21.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has an average rating of “Sell”.
Get Our Latest Stock Report on CNS Pharmaceuticals
About CNS Pharmaceuticals
CNS Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancers of the brain and central nervous system. Its research has centered on investigational therapies intended to address the challenges of treating tumors that affect these areas. The company’s lead candidate has been berubicin, an experimental anthracycline designed to cross the blood-brain barrier. CNS Pharmaceuticals has evaluated berubicin for glioblastoma, an aggressive form of brain cancer. The drug remains investigational and is not an approved treatment.
Further Reading
- Five stocks we like better than CNS Pharmaceuticals
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
Receive News & Ratings for CNS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CNS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
